Eli Lilly

News

Regeneron's COVID-19 antibody cocktail therapy hits safety p...

Regeneron’s coronavirus antibody cocktail therapy against COVID-19, famously used to treat president Donald Trump, has hit a safety issue after independent safety experts recommended it sho

News

US buys Lilly COVID antibody, as effectiveness questions rem...

The US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million if the drug gets Emergency Use Authorisation (EUA) – although its effectiveness has

News

The unprecedented challenge of pricing a coronavirus vaccine

NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial

Eli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run by the US National Institute of Allergy and Infectious Diseases (NIAID), as results to

News

Illustration of a nerve cell on a colored background with light effects

Lilly to buy private biotech Disarm Therapeutics for up to $...

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

News

Lilly pauses COVID-19 antibody trial after factory hits trou...

Eli Lilly has put a clinical trial of its COVID-19 antibody therapy on hold after FDA inspectors found serious quality control problems at the plant, according to press reports.

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s

Regeneron's COVID-19 antibody cocktail therapy hits safety p...

US buys Lilly COVID antibody, as effectiveness questions rem...

NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial

Lilly to buy private biotech Disarm Therapeutics for up to $...

Lilly pauses COVID-19 antibody trial after factory hits trou...

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Eli Lilly

Editor's Picks